SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial
SGLT2抑制剂达格列净用于新辅助蒽环类化疗联合或不联合曲妥珠单抗治疗的乳腺癌患者化疗诱导心脏毒性的一级预防:多中心PROTECT试验的理论基础和设计
期刊:Cardiooncology
影响因子:3.2
doi:10.1186/s40959-025-00368-9
Greco, A; Quagliariello, V; Rizzo, G; Tedeschi, A; Schirinzi, S; Turco, A; Galiazzo, M; Acquaro, M; De Amicis, M; Klersy, C; Ghio, S; Perrone, L; Paccone, A; Uccello, G; Canale, M L; Oliva, S; Guerra, F; De Luca, L; Maurea, N; Scelsi, L